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Solid tumors require new blood vessels for growth and metastasis, yet the biology of tumor-specific endo-
thelial cells is poorly understood. We have isolated tumor endothelial cells from mice that spontaneously
develop prostate tumors. Clonal populations of tumor endothelial cells expressed hematopoietic and mes-
enchymal stem cell markers and differentiated to form cartilage- and bone-like tissues. Chondrogenic differ-
entiation was accompanied by an upregulation of cartilage-specific col2a1 and sox9, whereas osteocalcin
and the metastasis marker osteopontin were upregulated during osteogenic differentiation. In human and
mouse prostate tumors, ectopic vascular calcification was predominately luminal and colocalized with the
endothelial marker CD31. Thus, prostate tumor endothelial cells are atypically multipotent and can undergo
a mesenchymal-like transition.INTRODUCTION
Tumor growth is angiogenesis dependent, and numerous studies
have reported the eradication of tumors in mice by targeting the
tumor vasculature (Folkman, 2007). Irrespective of these ad-
vances, very little is known about the biology of the endothelial
cells (ECs) that line tumor blood vessels. An assumption of anti-
angiogenesis therapy is that tumor endothelial cells (TECs) are
normal and derived from nearby, preexisting vessels. However,
there are several key differences between normal and tumor en-
dothelium. Tumor vessels are tortuous, leaky, and lack normal
hierarchical organization (Baluk et al., 2005). Isolated TECs
show increased drug resistance (Bussolati et al., 2003) and ex-
press distinct cell surface markers (Seaman et al., 2007; St Croix
et al., 2000). Our laboratory has recently reported that TECs have
aneuploid karyotypes (Hida et al., 2004) and expressErbB1 (Amin
et al., 2006). While the consequence of these abnormalities in
TECs is at present unclear, it is possible that abnormal TECs
could directly enable tumor growth, facilitate metastasis, and
lead to acquired drug resistance to antiangiogenic therapies.CaMost new blood vessels arise by co-option or sprouting of pre-
existing ECs. However, certain pathological conditions such as
ischemia and cancer are known to depend on both EC sprouting
and recruitment of circulating or bone marrow-derived endothe-
lial progenitor cells (EPCs). For example, increased numbers of
circulating EPCs can be detected following hindlimb ischemia
(Takahashi et al., 1999), and bone marrow-derived EPCs are re-
quired for tumor growth in some tumor models (Lyden et al.,
1999, 2001). On the other hand, studies using engraftment of
GFP+ bone marrow in tumor-bearing mice are equivocal. For ex-
ample, the degree of bone marrow involvement may be time and/
or tumor type dependent (Nolan et al., 2007). In some cases, di-
rect incorporation of GFP+ cells into tumor vessels has been ob-
served (Davidoff et al., 2001; Duda et al., 2006; Santarelli et al.,
2006; Yung et al., 2004). In other cases, GFP+ cells were perien-
dothelial, minimally incorporated into tumor vessels, or randomly
scattered throughout the tumor (Larrivee et al., 2005; Machein
et al., 2003; Rajantie et al., 2004; Udagawa et al., 2006). While
these studies formally prove that bone marrow-derived pro-
genitors are present in or around tumor blood vessels, oneSIGNIFICANCE
Endothelial cells line blood vessels that supply tumors with blood, nutrients, and oxygen during angiogenesis and act as
a conduit for the removal of waste products. However, tumor blood vessels are poorly formed and dysfunctional. We
have identified a multipotent, tumor-specific endothelial cell that undergoes calcification. Ectopic calcification of tumor en-
dotheliummay affect normal blood vessel function. For example, loss of the endothelial barrier in calcified tumor blood ves-
sels could enable tumor cell intravasation into the blood stream or impair contractility and blood flow. Vascular calcification
in tumors is easily discernible by standard histological techniques andmay be useful as a diagnostic tool. Tumor blood ves-
sel calcification adds to the growing list of abnormalities in tumor endothelium.ncer Cell 14, 201–211, September 9, 2008 ª2008 Elsevier Inc. 201
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true stem- or progenitor-like properties such as multipotency
and clonogenic ability.
Generally, stem cell fate is unidirectional and terminal. For ex-
ample, hematopoietic stem cells (HSCs) give rise to all blood cell
types of the lymphoid and myeloid lineages (Spangrude et al.,
1988), whereas mesenchymal stem cells (MSCs) give rise to
chondrocytes, osteoblasts, myoblasts, adipocytes, and neurons
(Prockop, 1997). However, an unexpected finding in cancer stem
cell research is that some tumor cells express genes associated
with multiple cell types. One of the best known examples are
melanoma tumor cells, which engage in vasculogenic mimicry
by expressing endothelial-specific genes (VE-cadherin) and
form fluid-transporting conduits (Hendrix et al., 2001). Thus, re-
programming of stem-like melanoma cells in the tumor microen-
vironment probably enables their adaptation and survival. It is
plausible that other stromal progenitors in the tumor microenvi-
ronment could also acquire a multipotent, mutable phenotype
due to reprogramming. Therefore, cellular plasticity may not be
limited to putative cancer-forming stem cells but could also be
common in tumor stromal cells such as ECs.
TRAMP (transgenic adenocarcinoma of the mouse prostate)
mice develop spontaneous prostate tumors beginning at pu-
berty as androgens drive T antigen expression in prostatic secre-
tory cells (Greenberg et al., 1995). An advantage of autochtho-
nous tumor models such as TRAMP is that tumors are
heterogeneous and subjected to selection pressure in the tumor
microenvironment as they develop. Thus, tumors in TRAMP mice
more closely mimic human cancers compared to xenografts. An-
giogenesis in TRAMP mice has been well characterized in vivo,
with vascular abnormalities beginning at the PIN (prostatic intra-
epithelial neoplasia) stage, which intensifies in poorly differenti-
ated tumors (Ozawa et al., 2005). However, isolation and culture
of ECs from TRAMP mice or any other autochthonous cancer
model have not yet been described.
In the present study, we isolated TECs from spontaneously
growing prostate tumors in TRAMP mice. Clonal populations of
TECs could be differentiated to form bone- and cartilage-like tis-
sues. These results suggest that TECs possess a stem/progenitor
cell property that distinguishes them fromECs throughout the nor-
mal vasculature but undergo atypical transdifferentiation, possi-
bly as a consequence of an osteogenic tumor microenvironment.
RESULTS
TECs Express Markers of Bona Fide Endothelium
Due to the small size of normal mouse prostate, it has been chal-
lenging to obtain enough tissue to isolate normal mouse prostate
ECs. Thus, mouse dermal endothelial cells (MDECs) from
C57BL/6 mice isolated in the same manner as TECs were used
as a normal counterpart. In both TECs and MDECs, there was
enriched expression of CD31, VEGFR-2, and vWF by semiquan-
titative RT-PCR (Figure 1A). However, CD146, a marker of ma-
ture or circulating ECs (Bertolini et al., 2006), was expressed in
MDECs but not TECs. On the other hand, expression of the
stem cell marker CD133 was between 2- and 3-fold higher in
TECs compared to MDECs. Both ECs expressed the stem/he-
matopoietic marker c-Kit but were negative for the monocyte
marker CD11b and the epithelial marker E-cadherin. The isolated202 Cancer Cell 14, 201–211, September 9, 2008 ª2008 Elsevier InTECs and MDECs had a cobblestone morphology and were uni-
formly positive for the endothelial markers CD31 and VE-cad-
herin but negative for the pericyte/mesenchymal marker aSMA
by immunostaining (see Figure S1 available online). The expres-
sion of additional markers including CD31, VE-cadherin, VEGFR-
2, PDGFR-b, SCA-1, CD34, and ID3 was evaluated by real-time
PCR or western blotting and is shown in Figure S1.
TECs Express the Mesenchymal Marker CD90 and
Form Blood Vessels When Engrafted into Nude Mice
Using flow cytometry, MDECs and TECs expressed comparable
levels of CD31 and VEGFR-2 as single peaks on the histogram
(Figure 1B). However, the EC/HSC marker CD34 was low to ab-
sent in TECs compared to MDECs, in good accord with the real-
time PCR analysis (Figure S1). On the other hand, the MSC
marker CD90 was lower in MDECs but was clearly expressed
in TECs. The HSC/MSC marker SCA-1 was not expressed in
TECs but was present in MDECs, consistent with SCA-1 expres-
sion in vascular endothelium (van de Rijn et al., 1989). Indeed,
SCA-1/CD31+ ECs were rare in TRAMP prostate tumors
in vivo and constituted only 1% of the total EC population
(Figure S2). In good agreement with the RT-PCR analysis,
CD133 was about 2-fold higher in TECs relative to MDECs.
Both MDECs and TECs were CD45, indicating absence of he-
matopoietic precursors. We found that the CD90+/CD31+ phe-
notype was consistent and stable in TECs from two separate iso-
lations and was maintained after prolonged periods in culture
(Figures 1C and 1D). To demonstrate EC functionality, GFP-ex-
pressing TECs were prepared by pMX-GFP retroviral infection
as described previously (Kitamura et al., 1995). MDECs and
TECs formed tube-like structures when cultured within a Matrigel
plug in vitro and were positioned at the luminal surface of eryth-
rocyte-filled blood vessels when injected in vivo (Figures 1E–1G).
Taken together, MDECs and TECs expressed the expected ma-
ture EC markers and functioned as bona fide endothelium, but
the expression of HSC and MSC markers in TECs was atypical.
TECs Form Mesenchymal-like Foci in Culture and
Demonstrate Alkaline Phosphatase Activity When
Cultured in Osteogenic Medium
Preliminary experiments indicated that MDECs and TECs were
not functional hematopoietic progenitors based on the absence
of colony-forming units in methylcellulose (data not shown).
TECs had an MSC-like profile (CD90+/CD34) and formed foci
in culture, reminiscent of MSCs (Figure 2A). However, the mor-
phology of TEC foci was distinct from that of MSC foci. TECs
were cuboidal and did not overlap at their margins, in contrast to
spindle-shaped, overlapping MSCs (Figure 2B). We next tested
whether TECs could differentiate to form mesenchymal lineages
such as osteocytes or adipocytes using selective media. In adi-
pogenic medium, about 50% of bone marrow-derived mesen-
chymal stem cells (BM-MSCs) differentiated to form lipid-storing
adipocytes based on oil red O staining (Figures 2C and 2D). On
the other hand, neither TECs nor MDECs showed any evidence
of oil red O staining when cultured under the same conditions. In
osteogenic medium, about 95% of BM-MSCs showed areas of
alkaline phosphatase (ALP) activity and about 10% of TECs
were ALP positive, indicating osteogenic differentiation. MDECs
were completely ALP negative. In TECs, ALP activity colocalizedc.
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(data not shown). These results suggested that TECs might
undergo a mesenchymal differentiation, prompting us to further
investigate this possibility.
TECs Undergo Mineralization after Prolonged
Culture in Osteogenic Medium
The von Kossa reaction detects calcification following the pre-
cipitation of silver phosphate at sites of high concentrations of in-
organic phosphate (particularly calcium phosphate formed by
osteoblasts). No von Kossa staining was present in MDECs or
TECs after 2 weeks in osteogenic medium (Figure 3A). However,
after 3 weeks in differentiation medium, von Kossa staining was
detected in TECs but not MDECs. In good accord with these re-
sults, the late markers of osteogenic differentiation osteopontin
(ssp1) and osteocalcin (bglap) were upregulated between
3- and 6-fold in TECs only after 3 weeks in osteogenic medium
(Figures 3B and 3C). These results were consistent with TEC
osteogenic differentiation in vitro.
Chondrogenic Differentiation of TECs
We further tested for TEC multipotency by incubating cells in
chondrogenic medium containing TGF-b for up to 2 weeks
Figure 1. Tumor Endothelial Cells Express
Markers of and Function as Bona Fide
Endothelium
(A) Isolated tumor endothelial cells (TECs) and
mouse dermal endothelial cells (MDECs) (both
passage 6) were analyzed for marker expression
by RT-PCR. The unfractionated tumor and the
CD31 non-EC fractions from the purification
step were also included on the gel.
(B) Fluorescence-activated cell sorting (FACS)
demonstrating uniform staining for the selected
markers in MDECs and TECs.
(C) FACS analysis of CD31+/CD90+ TECs from two
separate isolations. Three to four tumors were
pooled in each example, and ECs were isolated
and expanded in culture as described.
(D) The CD31+/CD90+ phenotype was stable and
was observable after prolonged culture.
(E) Both MDECs and TECs formed tube-like struc-
tures in a three-dimensional Matrigel culture
system in vitro.
(Fa–Fd) GFP-tagged MDECs and TECs formed
functional blood vessels when injected in vivo. Ma-
trigel plugs from day 10 were stained with anti-
GFP antibodies. The staining shows the luminal
position of the labeled ECs (dark brown staining).
The boxed regions are shown at higher magnifica-
tion at right. Visible erythrocytes within the vessels
are marked with an asterisk (*).
(G) Microvessel density over time (n = 3 mice per
group). Error bars represent ± SEM.
(Pittenger et al., 1999). TECs and BM-
MSCs formed visible pellets after approx-
imately 3–4 days in culture, while MDECs
never formed visible cell pellets under
these conditions. Chondrogenic differen-
tiation was confirmed by positive staining
for Alcian blue and col2a1 in the sectioned pellets (Figure 4A).
Normal mouse leg served as a control where articular cartilage
around the knee stained specifically for Alcian blue and col2a1.
Exchanging TGF-b1 for TGF-b3 resulted in no visible pellet
in TECs. Accordingly, TGF-b3 resulted in marked upregulation
of mRNAs for chondrocyte-specific col2a1 (11-fold) and the
master chondrogenic transcription factor, sox9 (12-fold) (Figures
4B and 4C).
TECs Can Be Grown as Single-Cell Clones
To rule out the possibility of contamination with mesenchymal
precursors, we prepared single-cell clones of TECs. Limiting di-
lution assays revealed single cells in individual wells that only oc-
casionally (<0.5%) formed proliferating colonies. A single, highly
proliferative clone of TECs obtained by limiting dilution (clone G9)
formed mesenchymal-like foci and flattened, cuboidal-shaped
cells when confluent (Figure 5A). We were unable to obtain sin-
gle-cell clones of MDECs by limiting dilution; however, clones
of MDECs could be readily obtained using cloning rings on col-
onies of sparsely plated cells. In TEC clone G9, CD31 double
staining showed coexpression with the MSC markers CD90,
CD44, and CD105, but not SCA-1 (Figure 5B). In contrast, an iso-
lated colony of MDECs were double positive for CD31, CD44,Cancer Cell 14, 201–211, September 9, 2008 ª2008 Elsevier Inc. 203
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were positive for all MSC markers but did not express CD31 as
expected.
Single-Cell Clones of TECs Undergo Osteogenic
and Chondrogenic Differentiation
Similar to the parental TEC population, TEC G9 underwent min-
eralization when cultured in osteogenic medium, indicated by
blackish-brown von Kossa staining (Figure 6A). TEC G9 also
formed a visible pellet in chondrogenic differentiation medium
that, when sectioned, stained positive for Alcian blue. However,
TEC G9 failed to undergo adipogenic differentiation, in contrast
to BM-MSCs, where intracellular lipids were stained with oil
red O. As expected, RT-PCR analysis showed that MDECs failed
to upregulate lineage-specific markers in all differentiation media
Figure 2. TECs Form Mesenchymal-like Foci In Vitro and Demon-
strate Alkaline Phosphatase Activity When Cultured in Osteogenic
Medium
(A) Foci in TECs and bone marrow-derived mesenchymal stem cells (BM-
MSCs) were counted and averaged from two 10 cm2 culture dishes.
(Ba–Bd) The morphology of TEC foci was cuboidal (Ba and Bb) with no overlap
between adjacent cells, while BM-MSCs were spindle-shaped with overlap-
ping borders (Bc and Bd). The boxed regions at left are shown in higher mag-
nification at right.
(Ca–Cf) BM-MSCs underwent adipogenic differentiation (Ca) and upregulated
alkaline phosphatase (ALP) activity (Cb) after culture in adipogenic or osteo-
genic medium, respectively. TECs did not undergo adipogenic differentiation
(Cc) but did show an upregulation of ALP activity in osteogenic medium
(Cd). MDECs did not differentiate under any test conditions (Ce and Cf). In
(Cc), (Ce), and (Cf), nuclei were counterstained with hematoxylin.
(D) The percentages of cells positive for oil red O and ALP from ten fields were
quantified and plotted on the graph.
Error bars in (A) and (D) represent ± SEM.204 Cancer Cell 14, 201–211, September 9, 2008 ª2008 Elsevier In(Figure 6B). Consistent with TECs’ failure to undergo adipogenic
differentiation, PPARg2 was almost undetectable in TEC G9
after culture in adipogenic medium, in contrast to BM-MSCs.
On the other hand, both TEC G9 and BM-MSCs upregulated
col2a1 and osteopontin mRNAs in chondrogenic and osteogenic
differentiation media, respectively. CD31 was coexpressed in
TECs and MDECs under all conditions but was qualitatively di-
minished in TECs cultured in differentiation media. An additional
clone (TEC A2) obtained by limiting dilution had a CD90+/CD31+
phenotype (data not shown) and could be induced to express
col2a1 and osteopontin, but not the adipogenic marker PPARg2
(Figure 6C). Taken together, these results suggest that TECs are
clonogenic and can undergo atypical multilineage differentiation
but do not undergo adipogenic differentiation characteristic of
bona fide BM-MSCs.
In Vivo Calcification of Prostate Tumor Cells
and Vascular Cells
To determine whether calcification is a feature of vascular cells in
clinical cancers, we used human prostate tissue arrays with tu-
mors of various grades. Low levels of von Kossa staining were
detected in 1 of 8 matched control prostate tissue specimens,
but 22 of 36 prostate tumor specimens (61%) showed varying
degrees of von Kossa staining (Figure 7A; Table 1). Eleven per-
cent of these specimens were characterized by densely black,
localized granules, characteristic for von Kossa staining,
whereas between 22% and 28% showed less robust staining
or individually stained cells throughout the tumor. Some von
Kossa staining was near necrotic regions in these tumors. While
no von Kossa staining was detected in blood vessels from nor-
mal prostate tissues, 11% of tumor specimens showed vascular
staining that was localized to the lumen or within the blood vessel
wall (Figure 7B; Figure S3). von Kossa staining was often local-
ized with the endothelial marker CD31 and the pericyte marker
aSMA, confirming the vascular-specific pattern (Figure 7C). Of
a total of 368 CD31+ tumor blood vessels counted, 13 vessels
(4%) were also stained with von Kossa, confirming the endo-
thelial sites of calcification. All of these data are summarized in
Table 1. Finally, in TRAMP mice, the chondrocytic marker col2a1
and von Kossa staining were also detected in prostate tumors
and tumor blood vessels (Figure S4). Thus, TECs in clinical pros-
tate cancers and TRAMP mice are characterized by an atypical
transdifferentiation into mesenchymal lineages.
DISCUSSION
This study describes the isolation and characterization of TECs
from spontaneously growing prostate tumors in TRAMP mice.
Similar to normal ECs, TECs had a cobblestone or cuboidal mor-
phology and expressed markers such as CD31, VE-cadherin,
and VEGFR-2. In contrast, TECs did not express SCA-1,
CD34, or CD146, markers common to most vascular ECs, but
did express CD90. CD90, also known as Thy-1, is a marker
that is not typically found in quiescent endothelium (Lee et al.,
1998) but is instead expressed by mesenchymal progenitors. In-
terestingly, Thy-1 was also found to be highly expressed in hu-
man tumor-derived ECs in the seminal study by St Croix et al.
(2000). TECs were also clonogenic and differentiated to form
bone- and cartilage-like tissues when cultured in selectivec.
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were they contaminated with tumor cells, as indicated by ab-
sence of T antigen expression in vivo and in vitro (Figure S5).
However, absence of T antigen expression in TECs does not pre-
clude the possibility that tumor epithelial cell transformation in
the prostate does not result in epigenetic alterations in the asso-
ciated stromal cells, as documented in human breast carcinoma
(Hu et al., 2005). Taken together, several lines of evidence sug-
gest that TECs can undergo transdifferentiation into mesenchy-
mal lineages: (1) single-cell clones of TECs underwent differenti-
ation into bone and cartilage; (2) potential contamination with
bona fide MSCs was precluded because TECs could only differ-
entiate into bone and cartilage but not adipocytes; (3) TECs ex-
pressed EC markers such as CD31 and VE-cadherin, which are
absent in MSCs; and (4) CD31 protein and bone-related differen-
tiation markers (ALP) were present in the same cells.
What is the origin of TECs? The majority of ECs in tumor blood
vessels probably arise by sprouting from nearby, preexisting
ECs. However, the turnover of ECs in vivo is extremely slow (ap-
proximately one cell division every 1000 days) but increases dra-
matically during active angiogenesis. Hierarchies of resident
EPCs with different clonogenic and proliferative abilities reside
throughout the vasculature, even into adult life (Ingram et al.,
2004, 2005). Resident EPCs may form the immediate angiogenic
response to tissue injury by circumventing systemic bone mar-
row involvement (O’Neill et al., 2005). Similarly, tissue-resident
progenitors may form the immediate response to tumor angio-
genesis. For example, multipotent CD34 tissue-resident pro-
genitors with potential to differentiate into mesodermal and mes-
enchymal lineages (Jiang et al., 2002; Reyes et al., 2001) and
incorporate into tumor blood vessels have recently been de-
scribed (Bussolati et al., 2005). However, the identification and
Figure 3. TECs Undergo Mineralization after Pro-
longed Culture in Osteogenic Medium
(Aa–Ah) MDECs were negative for von Kossa staining in con-
trol and osteogenic medium after a 2 week (Aa and Ac) or 3
week incubation (Ab and Ad). TECs were also von Kossa neg-
ative after the 2 week incubation (Ae and Ag), but intense von
Kossa staining, indicating calcification, was present in TECs
after 3 weeks (Af and Ah). Nuclei were counterstained with
hematoxylin.
(B and C) After 3 weeks in osteogenic medium, the late
markers of osteogenic differentiation osteopontin and osteo-
calcin were upregulated 3-fold and 5-fold, respectively,
in TECs.
relative contribution of tissue-resident progenitors
to tumor vasculature has been difficult to address,
probably due to the rarity of these cells in adult
tissue.
On the other hand, bone marrow-derived and cir-
culating EPCs play a definitive role in tumor growth
in some tumor models, where they may mediate
a postulated metastatic switch (Gao et al., 2008).
Furthermore, the ID1+/ ID3/ knockout mouse,
which has delayed tumor growth and poorly vascu-
larized tumors, fails to incorporate bone marrow-
derived progenitors into tumor blood vessels
(Lyden et al., 1999, 2001). While our isolated TECs strikingly
overexpressed ID3 in culture, they did not express the HSC
markers SCA-1 or CD34. Together, this was an unusual expres-
sion profile for an EC, but it was not entirely indicative of a bone
marrow-derived progenitor. Instead, the complete absence of
SCA-1 expression in TECs and the rarity of CD31+/SCA-1
ECs in prostate tumors in vivo could indicate a possible
tissue-resident, rather than a bone marrow-derived, origin.
While it appears that TECs are progenitor- or stem-like cells,
normal ECs do not usually undergo a mesenchymal transi-
tion—two exceptions are the rare cardiac valve ECs in develop-
ing cardiac cushions (Paruchuri et al., 2006) and embryonic ECs
in the dorsal aorta (DeRuiter et al., 1997). It is interesting that
a common mesodermal ancestor for ECs and pericytes has
been postulated (Yamashita et al., 2000) given that pericytes
are not terminally differentiated cells and can differentiate into
fibroblasts, osteoblasts, chondrocytes, and adipocytes (Doherty
et al., 1998; Farrington-Rock et al., 2004). Furthermore, MSCs
themselves may give rise to endothelium under pathobiological
conditions (Wang et al., 2005). One possibility is that some
TECs arise from mesenchymal progenitors and undergo a mes-
enchymal-like differentiation due to factors in the tumor microen-
vironment. By culturing isolated TECs in defined differentiation
media, we were able to recapitulate this phenomenon in vitro.
Thus, tumor stromal cells, like cancer stem cells, may be capable
of multipotent differentiation into atypical lineages (Hendrix et al.,
2007; Topczewska et al., 2006).
Ectopic bone and cartilage, osteoclast-like cells, and calcify-
ing vascular cells have been described in diseased blood vessel
wall (Tintut et al., 2003; Watson et al., 1994). For example, vas-
cular calcifications are common in the medial layer around ath-
erosclerotic plaques. Angiogenesis is abundant in these areasCancer Cell 14, 201–211, September 9, 2008 ª2008 Elsevier Inc. 205
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around the calcified deposits (Johnson et al., 2006). The interac-
tions between bone morphogenetic proteins, VEGF, pericytes,
and resident osteoprogenitor cells are thought to account for car-
diac valve and arterial calcification (Collett and Canfield, 2005).
Notably, in most vascular diseases, calcification is typically ob-
served in the extracellular matrix surrounding smooth muscle
cells in the arterial wall, whereas in human prostate tumors, we
observed calcification mainly at the luminal side of capillaries.
Therefore, at least in prostate tumors, TECs appear to undergo
a mesenchymal-like transition to form bone-like tissues. Interest-
ingly, TECs cultured in osteogenic medium in vitro transitioned
from cobblestone- into spindle-shaped cells. It is possible that
loss of cell-to-cell contact in calcified tumor blood vessels
in vivo could impair blood flow or enable tumor cell intravasation
into the bloodstream, facilitating metastasis.
An osteogenic tumor microenvironment in prostate cancer
has been hypothesized to facilitate metastasis to bone (Chung,
Figure 4. Chondrogenic Differentiation of TECs
(Aa–Ai) BM-MSCs and TECs formed a visible pellet within 3–4 days that was
maintained for the 2 week experiment. Formalin-fixed, paraffin-embedded
pellets were sectioned and stained with hematoxylin and eosin (H&E; Aa and
Ad), Alcian blue (Ab and Ae), or col2a1 antibodies (Ac and Af). An H&E-stained
section of mouse leg is also shown (Ag). Articular cartilage around the knee
stained specifically with Alcian blue (Ah) and col2a1 (Ai). The 1 mm scale bar
applies to panels (Aa)–(Ag); the 50 mM scale bar applies to panels (Ah) and (Ai).
(B and C) The markers of chondrogenic differentiation col2a1 and sox9 were
upregulated12-fold in TECs in the presence of TGF-b3. No pellet was formed
in TECs when TGF-b1 was substituted.206 Cancer Cell 14, 201–211, September 9, 2008 ª2008 Elsevier Inc2003; Edlund et al., 2004). For example, the expression of
bone-specific proteins in prostate tumor cells may enable their
survival once they reach the bone microenvironment (Koeneman
Figure 5. TECs Can Be Grown as Single-Cell Clones
(Aa–Ag) TECs infected with retroviral GFP were plated as single cells in 96-well
plates. While most single cells never proliferated, occasional colonies could be
obtained from single cells (Aa) that proliferated into clonal populations 7 days
(Ab) and 12 days (Ac) after seeding. TEC clone G9 obtained by limiting dilution
formed foci (Ad) and highly proliferative, cuboidal-shaped cells (Ae). Single-cell
clones could not be obtained in MDECs by limiting dilution, but sparsely plated
MDECs readily formed colonies that could be selected using cloning rings.
MDECs are shown 3 days (Af) and 6 days (Ag) after initial plating, but before
selection using cloning rings.
(B) Flow cytometry was carried out on live cells using the indicated antibodies.
Consistent with the parental TECs, clone G9 coexpressed CD90 and CD31. The
additional mesenchymal markers CD44 and CD105 were also present while
SCA-1 was absent in TECs. A colony of MDECs selected using cloning rings ex-
pressed CD31 in addition to CD44, CD105, and SCA-1, but CD90 was low to
absent. BM-MSCs expressed all markers with the exception of CD31..
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restricted markers such as ALP, osteocalcin, and osteopontin in
TECs. Osteopontin is widely used as a biomarker for advanced
disease and is a known mediator of bone metastasis (Kang
et al., 2003; Nemoto et al., 2001; Wai and Kuo, 2008). Osteopon-
tin contains an RGD motif that mediates cell-to-cell interactions
through integrins facilitating anchorage-independent growth and
invasion (Allan et al., 2006). Thus, osteopontin expression in
TECs could be chemotactic for tumor cells, enabling their inter-
action with blood vessels and allowing for intravasation. Simi-
Figure 6. Single-Cell Clones of TECs Undergo Osteogenic and
Chondrogenic Differentiation
(Aa–Af) After 3 weeks in osteogenic medium, TEC clone G9 was formalin-fixed
and stained with von Kossa solution. Brownish/black staining in G9 (Aa) and
BM-MSCs (Ab) was evident, indicating calcification. Chondrogenic differenti-
ation was also observed in clone G9 (Ac) and BM-MSCs (Ad), indicated by
a visible pellet after 2 weeks in chondrogenic medium that stained with Alcian
blue. In adipogenic medium, no oil red O-positive cells were observed in clone
G9 (Ae), in contrast to BM-MSCs (Af).
(B) Semiquantitative RT-PCR analysis for differentiation markers in each cell
type cultured in the indicated differentiation medium. The asterisk (*) indicates
that 5% serum was included in the chondrogenic medium because MDECs did
not survive in the serum-free conditions.
(C) col2a1 and osteopontin, but not PPARg2, were inducible in an additional
TEC clone (A2) cultured in differentiation medium.Clarly, serum osteocalcin is elevated in patients with bone-meta-
static prostate cancer, where it is primarily a biomarker of
bone deposition (Hegele et al., 2007). sox9, a transcriptional reg-
ulator of col2a1 during chondrogenesis, was inducible in TECs
and is expressed in prostate cancer cells, where it regulates an-
drogen receptor expression (Wang et al., 2007). The chondro-
cytic marker col2a1, which has not been described as a marker
Figure 7. In Vivo Calcification of Prostate Tumor Cells and Vascular
Cells
(Aa–Af) Representative images of von Kossa staining in normal prostate (Aa–
Ac) and prostate tumors (Ad–Af). Calcification in tumors was often associated
with highly necrotic regions.
(Ba–Bf) von Kossa staining in tumor blood vessels from three different tumors
showing the luminal localization (Aa, Ac, and Ae). Boxed regions in the upper
row are shown in higher magnification in the lower row (Ab, Ad, and Af). The
inset in (Ab) shows a higher magnification of the boxed region. Nuclei in (A)
and (B) were counterstained with nuclear fast red.
(Ca–Cd) Colocalization of the endothelial marker CD31 (Ca and Cb) and the
pericyte marker aSMA (Cc and Cd) with von Kossa staining in tumor blood ves-
sels. The boxed regions at left are shown in higher magnification at right. CD31
and aSMA were detected using an alkaline phosphatase-conjugated second-
ary antibody and appear red in the figure. No counterstain was used. Lu = lu-
men; the asterisk (*) marks a visible erythrocyte within the vessel lumen in (Cd).ancer Cell 14, 201–211, September 9, 2008 ª2008 Elsevier Inc. 207
Cancer Cell
Multipotent Tumor Endothelial CellsTable 1. Quantification of von Kossa Staining in Normal Prostate and Prostate Tumors
Number of Specimens with von
Kossa Staining
Number of Specimens with von
Kossa Staining in Blood Vessels
Total Number of CD31+/von Kossa+
Blood Vessels
Normal prostate 1/8a 0/8 ND
Prostate tumor (total) 22 (61 %) 4/36 (11 %) 13/368 (4 %)
Low 10 (28 %)
Medium 8 (22 %)
High 4 (11 %)
Prostate tumor cores of various grades (n = 36) were matched with adjacent normal prostate tissue (n = 8). ND = none detected.
a One normal prostate had low levels of diffuse von Kossa staining, but not in blood vessels.of tumor blood vessels, was also present in prostate tumor spec-
imens and tumor endothelium, but not in normal prostate. Thus,
factors normally expressed in bone, cartilage, or prostate tumor
cells are inducible in TECs but not normal ECs. One possibility
is that osteogenic factors in the tumor microenvironment may
induce the osteogenic and chondrogenic differentiation of tis-
sue-resident or bone marrow-derived progenitors in the tumor
stroma.
In conclusion, it has long been assumed that TECs were iden-
tical to normal ECs. For example, human umbilical vein endothe-
lial cells (HUVECs) are a common surrogate for studying the ef-
ficacy of antiangiogenic drugs in vitro. However, morphological
(McDonald and Choyke, 2003), pathophysiological (Hagendoorn
et al., 2006), cytogenetic (Hida et al., 2004; Streubel et al., 2004),
epigenetic (Grover et al., 2006), gene expression (St Croix et al.,
2000), and, here, atypical multipotent plasticity have all been
demonstrated in TECs. It will now be important to determine
whether the mutable properties of prostate TECs relate to abnor-
malities in tumor blood vessels, whether vascular calcification
might enable tumor cell metastasis or impair blood flow, and
whether vascular calcification in tumors could be used as a
diagnostic tool.
EXPERIMENTAL PROCEDURES
Cells and Media
TECs and MDECs were cultured in low-glucose DMEM containing antibiotic/
antimycotic, 10% FBS, 10% Nu-Serum IV (BD PharMingen), 3 ng/ml bFGF,
50 ng/ml VEGF (both bFGF and VEGF were kind gifts from the NCI Biological
Resources Branch Preclinical Repository), and 100 mg/l porcine heparin
(Sigma-Aldrich). BM-MSCs were cultured in the same medium, but with
20% FBS added. All cells were used between 12 and 15 passages.
Mice
TRAMP mice (C57BL/6) were housed in compliance with Children’s Hospital
Boston guidelines, and all animal-related protocols were approved by the In-
stitutional Animal Care and Use Committee. Mice were genotyped at weaning
(Transnetyx).
TEC Isolation
Large prostate tumors typically arose by 30–40 weeks of age in TRAMP mice.
Tumors were minced with fine scissors into pieces < 1 mm in size. Minced tu-
mors were then transferred to HBSS containing 1 mg/ml collagenase type I
(Worthington Biochemical Corporation) and 100 mg/ml DNase (Worthington)
and placed in a 37C water bath. The sample was alternately vortexed and dis-
rupted by trituration every 10 min over a 30–45 min period until the mixture
could be freely pipetted. Next, tumor digests were filtered with a 100 mm cell
strainer and centrifuged at 1200 rpm for 15 min. The cell pellet was then resus-
pended in 13 PharmLyse B (BD PharMingen), and left at room temperature for
10 min. After the 10 min incubation, the sample was centrifuged at 1200 rpm208 Cancer Cell 14, 201–211, September 9, 2008 ª2008 Elsevier Infor 5 min, and the cell pellet was resuspended in 10 ml of MACS buffer (de-
gassed phosphate-buffered saline [PBS] containing 2 mM EDTA and 0.5%
BSA) and filtered again through a 70 mm cell strainer. Cells were centrifuged
as before, and approximately 250 ml of packed cells was resuspended in
500 ml of MACS buffer. Ten micrograms of rat anti-mouse CD31 antibody
(BD PharMingen) was added to the resuspended cells, which were incubated
at room temperature for 10 min. After the 10 min incubation, cells were centri-
fuged as above and washed twice with MACS buffer. The cells were resus-
pended in 320 ml of MACS buffer, and 80 ml of goat anti-rat magnetic beads
was then added (Miltenyi Biotec). The mixture was left at room temperature
for another 10 min and then filtered through a 100 mm cell strainer before being
passed over a magnetic column (Miltenyi Biotec). After washing the column
with 8–10 ml of MACS buffer, the bound cells were eluted. The eluted cells
were centrifuged and washed three times with culture medium before plating
into a T-75 flask coated with 10 mg/ml of human fibronectin (Biomedical Tech-
nologies). After 4–6 weeks, cells were washed with PBS and detached using
3 ml of Accutase (Innovative Cell Technologies). Cells were centrifuged,
washed once with MACS buffer, and resuspended in 200 ml of MACS buffer
containing 10 mg of rat anti-mouse ICAM-2 antibodies (BD PharMingen). The
purification procedure was repeated as above. The purified ECs eluted from
the magnetic column were washed twice with culture medium and then seeded
into a single well of a six-well or 24-well plate. The use of cloning rings was
often necessary as a final method for obtaining pure endothelial cell cultures.
Differentiation
For adipogenic differentiation, cells were seeded at a density of 50,000 cells/
well in 12-well plates. The next day, the medium was removed and replaced
with DMEM containing 1% antibiotic/antimycotic, 10% FBS, 5 mg/ml insulin,
1 mM dexamethasone, 0.5 mM isobutylmethylxanthine, and 60 mM indometha-
cin (all reagents purchased from Sigma-Aldrich). After 2 weeks, cells were
washed, fixed in formalin, and stained with oil red O to detect lipid. For osteo-
genic differentiation, cells were plated into two-well chamber slides in medium
containing DMEM, 10% FBS, 1% antibiotic/antimycotic, 1 mM dexametha-
sone, 10 mM b-glycerophosphate, and 100 mM ascorbic acid 2-phosphate.
After 1–3 weeks, cells were washed, fixed in formalin, and stained for ALP or
von Kossa solution (Diagnostic BioSystems). For chondrogenic differentiation,
cells were detached with Accutase, washed, adjusted to 13 106 cells/ml, and
centrifuged. The medium was carefully aspirated and replaced with high-glu-
cose DMEM containing 1% antibiotic/antimycotic, 10 ml/ml insulin-transferrin-
selenium, 1 mM dexamethasone, 20 ng/ml TGF-b1 or TGF-b3 (R&D Systems),
and 100 mM ascorbic acid 2-phosphate. In all experiments, control medium
was DMEM containing 10% FBS with 1% antibiotic/antimycotic.
Fluorescence-Activated Cell Sorting
Cell were detached with Accutase, washed, and resuspended in PBS/0.1%
BSA containing the indicated conjugated antibodies (all purchased from
BD PharMingen, with the exception of CD90, CD105, and CD44 antibodies,
which were purchased from eBioscience). After two washes, cells were ana-
lyzed using a BD FACSCalibur System (BD Biosciences).
RT-PCR
Total cellular RNA was extracted using an RNeasy kit according to the manu-
facturer’s directions (QIAGEN). Five micrograms of RNA was subjected toc.
Cancer Cell
Multipotent Tumor Endothelial Cellsreverse transcription by standard methods. Two microliters of cDNA was then
used in a 50 ml PCR reaction containing a 1 mM concentration of each primer, 1
ml of dNTPs (10 mM stock), 5 ml of 103 PCR buffer with MgCl2 (Invitrogen), and
0.4 ml of Taq DNA polymerase (Roche).
Immunofluorescence
Cells were seeded at a density of 10,000 cells per well in fibronectin coated
eight-well chamber slides. Confluent cells were washed twice with PBS and
then fixed with ice-cold 100% methanol at 20C for 20 min. The fixed cells
were rinsed briefly with PBS and then blocked for 1 hr at room temperature
with PBS containing 5% BSA. After blocking, antibodies were added overnight
at 4C in a humidified chamber. The next day, cells were rinsed with PBS and
then blocked again for 30 min at room temperature. Secondary antibodies
were added, and the cells were incubated for an additional 1 hr at room tem-
perature protected from light. Finally, cells were washed with PBS and then
mounted using Gel Mount (Biomeda) containing 0.4 mg/ml 40,6-diamidino-
2-phenylindole (DAPI).
Matrigel Plug Assay
Two million TECs and MDECs were washed and resuspended in 100 ml of phe-
nol red-free Matrigel. For the in vitro tube-forming assay, 50 ml of this suspen-
sion was pipetted into single wells of a 24-well plate and then placed at 37C
for 20 min. Each well was then filled with 1 ml of EC growth media. For the
in vivo experiment, 2 3 106 TECs or MDECs were resuspended in Matrigel
and injected into the lateral flank of 8-week-old nu/nu mice. Implants were
removed on the indicated days and fixed in formalin overnight.
Tissue Microarrays
Commercially available human prostate adenocarcinoma tissue arrays were
purchased from Biomax US. The array had 48 cores in duplicate with tissue-
matched controls. Under the guidelines of the Clinical Investigation Policy
and Procedure Manual at Children’s Hospital Boston, commercially available
specimens that cannot be linked to subjects are exempt from IRB review.
SUPPLEMENTAL DATA
The Supplemental Data include five figures and can be found with this article
online at http://www.cancercell.org/cgi/content/full/14/3/201/DC1/.
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